Summary: This global Fortune 500 company is one of the top three manufacturers in the pharmaceutical ingredients market. Working with BayGroup International, it executed an initiative to address increasing competition from low-priced offshore suppliers. The results: a 7.5% increase in average deal size, and significant gains in revenue volume, "share of wallet," and net profit.

